✉news TechnologyTechnology first seen 3 d ago, last 3 d ago, peak #32
ImmunityBio's Anktiva wins US label expansion for bladder cancer
Original: ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion
ImmunityBio's bladder cancer drug Anktiva has received a label expansion in the United States, widening the approved uses of the therapy. The approval allows the immunotherapy to be used in more patients with the disease, strengthening ImmunityBio's position in the bladder cancer treatment market and giving clinicians an additional option for care.
Why now: Regulatory label expansions are significant commercial and clinical milestones, drawing attention from investors, patients and oncologists.
ImmunityBioAnktivaUnited StatesFDA
Evidence
- ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion · Pharmaceutical Technology
API: https://socialmediatrends-api.osmike.com/v1/trends/2355272